PRPH - プロフェイズ・ラブズ （ProPhase Labs Inc.）

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded. As a result, investors can be taken on a wild ride. Nevertheless, biotech penny stocks – or more generally biotech stocks under $10 – offer massive, possibly life-changing upside potential. Due to their underlying unpredictability, when these enterprises do occasionally hit one out of the park, their shares can skyrocket. So, astute investors will throw some pocket change at this subsegment because your money may go very far. At the same time, you can also implode your portfolio if you’re not careful. Again, the key phrase here is pocket change. If you acknowledge the risks and are ready to roll the dice, these biotech stocks with huge potential just might fit the bill. PRPH ProPhase Labs $7.59 ZOM Zomedica $0.20 MXCT MaxCyte $4.83 CRMD CorMedix $4.63 SRTS Sensus Healthcare $4.74 OCUP Ocuphire Pharma $5.30 MTNB Matinas BioPharma $0.60 ProPhase Labs (PRPH) Source: aslysun / Shutterstock.com Founded in 1989, ProPhase Labs (NASDAQ: PRPH ) is a next-generation biotech, genomics, and diagnostics company.

Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its newly redesigned corporate website showcasing the company''s diverse portfolio of subsidiaries and offerings, which include Nebula Genomics, ProPhase Diagnostics, ProPhase BioPharma, Pharmaloz Manufacturing, Inc., and TK Supplements.

NEWARK, DE / ACCESSWIRE / April 17, 2023 / The Short-Read Sequencing Market size is projected to be valued at US$ 6,322.03 million in 2023 and is expected to rise to US$ 34,401.22 million by 2033. The sales of short-read sequencing are projected to expand at a significant CAGR of 18.46% during the forecast period. The global short-read sequencing market is a notably expanding industry that includes technologies and services that enable high-throughput sequencing of DNA or RNA fragments. Short-read sequencing technologies can produce millions or billions of short DNA or RNA reads, with typical lengths ranging from 50 to 300 base pairs. Drivers and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16920 Several key factors are driving the short-read sequencing market, including rising demand for genomic analysis in clinical diagnostics, personalized medicine, drug discovery, and agriculture.

ProPhase Labs, Inc. (NASDAQ:NASDAQ:PRPH) Q4 2022 Earnings Conference Call March 28, 2023 11:00 AM ETCompany ParticipantsTed Karkus - Chairman and Chief Executive OfficerConference Call…

ProPhase Labs has strong fundamentals and a lot of upside potential with new business acquisitions. Click here to see its growth catalysts and potential headwinds.

The following slide deck was published by ProPhase Labs, Inc.

GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24 th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

ProPhase Labs, Inc (NASDAQ:NASDAQ:PRPH) Q2 2022 Earnings Conference Call August 11, 2022, 09:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference…

ProPhase Labs press release (NASDAQ:PRPH): Q2 GAAP EPS of $0.40 beats by $0.24.Revenue of $29.09M (+218.3% Y/Y) beats by $5.77M.Shares +4.96% PM.

ProPhase Labs (PRPH) stated Tuesday that it has received Board''s approval to repurchase up to $6M of its common shares. The buyback plan is to be effective three business days after…

ProPhase Labs has expanded its in-house testing capabilities for the diagnostics of the new clinical chemistry, immunoassay, hematology, hemostasis, and urinalysis analyzers.

DSS (DSS) shares popped around 17% after the company announced on Thursday the licensing of Impact BioMedical''s Linebacker portfolio to ProPhase Labs (PRPH).Global BioLife, a subsidiary…

ProPhase Labs (PRPH) on Thursday said its unit had entered into a licensing agreement with Global BioLife for two inhibitors that can be used to treat multiple indications, with an…

Garden City, NY, July 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it will host a live webcast on Thursday, July 21, 2022, at 11:30 a.m. EST / 8:30 a.m. PST. ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the webcast and review the latest developments at ProPhase Labs and